Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

Market Cap	22.49B
Revenue (ttm)	6.68B
Net Income (ttm)	2.22B
Shares Out	770.09M
EPS (ttm)	2.88
PE Ratio	11.56
Forward PE	30.86
Dividend	1.28 (3.84%)
Ex-Dividend Date	Jul 12, 2024

Volume	6,446,200
Average Volume	5,462,919
Open	32.97
Previous Close	32.73
Day's Range	32.81 - 33.63
52-Week Range	26.16 - 39.05
Beta	0.89
RSI	47.28
Earnings Date	Aug 15, 2025

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2024, SHA:600329's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.